Table 2 Primary outcome measures comparing rosuvastatin and aspirin to placebo, with 12 weeks follow-up as the primary comparison

 Overall^a

–

–

–

0.296

–

–

0.467

–

–

 Baseline

32.6 (6.1)

32.6 (5.5)

32.3 (6.5)

 4 weeks

23.1 (10.2)

22.7 (9.7)

24.0 (9.2)

− 1.6 (− 5.7, 2.5)

− 0.21

0.357

− 1.7 (− 5.4, 2.0)

− 0.24

0.0 (− 4.3, 4.3)

 8 weeks

19.1 (10.7)

22.0 (11.1)

22.1 (10.6)

− 3.7 (− 8.1, 0.6)

− 0.43

0.854

− 0.4 (− 4.7, 3.9)

− 0.07

3.5 (− 8.3, 1.2)

 12 weeks

17.2 (11.0)

22.9 (12.0)

20.4 (12.4)

0.089

− 4.2 (− 9.1, 0.6)

− 0.44

0.433

1.9 (− 2.8, 6.6)

0.16

− 6.4 (− 11.7, 1.2)

 26 weeks^d

16.0 (12.3)

15.7 (10.4)

13.2 (10.4)

0.487

1.9 (− 3.4, 7.2)

0.12

0.353

2.5 (− 2.7, 7.6)

0.10

0.3 (− 6.0, 6.7)